Bafiertam is a drug owned by Banner Life Sciences Llc. It is protected by 21 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2035. Details of Bafiertam's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10918616 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US10918615 | Fumarate esters |
Feb, 2035
(9 years from now) | Active |
| US11590095 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US9326965 | Controlled release fumarate esters |
Feb, 2035
(9 years from now) | Active |
| US9814692 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US9636318 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US9814691 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US10105336 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US9820961 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US10098863 | Fumarate esters |
Feb, 2035
(9 years from now) | Active |
| US11903918 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Feb, 2035
(9 years from now) | Active |
| US9511043 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US9517209 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US9566259 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US9326947 | Controlled release fumarate esters |
Feb, 2035
(9 years from now) | Active |
| US10105335 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US10105337 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US10918617 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
| US9636319 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US10945985 | Fumarate ester dosage forms |
Feb, 2035
(9 years from now) | Active |
| US9820960 | Fumarate ester pharmaceutical compositions |
Feb, 2035
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Bafiertam's patents.
Latest Legal Activities on Bafiertam's Patents
Given below is the list of recent legal activities going on the following patents of Bafiertam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9517209 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jun, 2024 | US9511043 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903918 |
| Recordation of Patent Grant Mailed
Critical | 20 Feb, 2024 | US11903918 |
| Patent Issue Date Used in PTA Calculation
Critical | 20 Feb, 2024 | US11903918 |
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903918 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903918 |
| Email Notification
Critical | 20 Feb, 2024 | US11903918 |
| Email Notification
Critical | 01 Feb, 2024 | US11903918 |
| Issue Notification Mailed
Critical | 31 Jan, 2024 | US11903918 |
US patents provide insights into the exclusivity only within the United States, but
Bafiertam is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Bafiertam's family patents as well as insights into
ongoing legal events
on those patents.
Bafiertam's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bafiertam's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 27, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bafiertam Generics:
There are no approved generic versions for Bafiertam as of now.
Alternative Brands for Bafiertam
Bafiertam which is used for managing symptoms of multiple sclerosis., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Bafiertam
Bafiertam is a drug owned by Banner Life Sciences Llc. It is used for managing symptoms of multiple sclerosis. Bafiertam uses Monomethyl Fumarate as an active ingredient. Bafiertam was launched by Banner Life Sciences in 2020.
Approval Date:
Bafiertam was approved by FDA for market use on 28 April, 2020.
Active Ingredient:
Bafiertam uses Monomethyl Fumarate as the active ingredient. Check out other Drugs and Companies using Monomethyl Fumarate ingredient
Treatment:
Bafiertam is used for managing symptoms of multiple sclerosis.
Dosage:
Bafiertam is available in capsule, delayed release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 95MG | CAPSULE, DELAYED RELEASE | Prescription | ORAL |